![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Articles
The Specialty Pharmacy: A One-to-One Personalized Approach
Maybe you’ve noticed: medications are getting more complicated, more personalized, and more expensive.
Look at some of the recent drugs approved for cancer, hepatitis C...
Articles
Diabetes Symptoms & Complications
Symptoms
People with type 1 or type 2 diabetes may have a range of symptoms. These symptoms might include:
Frequent urination (polyuria) -- often at...
Articles
Diabetes Risk Factors & Prevention
Risk Factors
Risk factors are characteristics that can predispose you to developing a condition or disease. Just because you have one or more risk factors...
Drug Research
Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT (Amphetamine Extended-Release Orally Disintegrating Tablet) for ADHD
Neos Therapeutics, Inc, a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD) announced...
Drug Research
FDA Approves Zepatier (elbasvir and grazoprevir) for Chronic Hepatitis C Genotypes 1 and 4
The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus...
Articles
Teva’s Dedication and Commitment Recognized by Patients
Fourth annual PatientView survey identifies Teva as a “Corporate Star” in the eyes of patients. Making medicines accessible is key to patient groups.
Teva's Dedication...
Drug Research
AstraZeneca to collaborate with Cancer Research UK in screening for new cancer medicines at the AstraZeneca MRC UK Centre for Lead Discovery
AstraZeneca and Cancer Research UK today announced that they have signed a memorandum of understanding through which Cancer Research UK drug discovery investigators would...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read